Nanjing Vazyme Biotech (SHA:688105) partnered with Shenzhen BGI Genomics to develop genetic products, according to a Shanghai Stock Exchange filing on Saturday.
Both parties signed a five-year agreement to develop reproductive genetics and other genetic projects that will prevent tumors, dementia and other diseases.
The agreement is valid until March 5, 2030, the Chinese biotechnology company said.
Vazyme's shares closed over 2% higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.